## Edgar Filing: BioAmber Inc. - Form 4

BioAmber Ine Form 4	с.									
January 27, 2	016									
FORM	4		GEOU			GHANGE			PPROVAL	
Washington, D.C. 20549									3235-0287	
Check this box if no longer								Expires:	January 31, 2005	
subject to STATEMENT OF CHANGES IN BENEFICIAL (Section 16.   Form 4 or Form 5   Form 5 Filed pursuant to Section 16(a) of the Securities Exch								Estimated burden hou response	average urs per	
obligation may conti <i>See</i> Instru- 1(b).	nue. Section 17(	a) of the l	Public U	tility Hol	ding Cor		of 1935 or Secti			
(Print or Type R	esponses)									
1. Name and Address of Reporting Person <u>*</u> Orecchioni Fabrice			2. Issuer Name <b>and</b> Ticker or Trading Symbol			5. Relationship of Reporting Person(s) to Issuer				
<u> </u>			BioAmber Inc. [BIOA]				(Check all applicable)			
			3. Date of Earliest Transaction (Month/Day/Year) 01/26/2016			Director 10% Owner X Officer (give title Other (specify below) below)				
RENE-LEVI SUITE 4310	ESQUE BLVD '	WEST,					· · · · · · · · · · · · · · · · · · ·	Operations Off	icer	
			4. If Amendment, Date Original Filed(Month/Day/Year)			6. Individual or Joint/Group Filing(Check Applicable Line)				
MONTREA	L, A8 H3B 4W8		1		-)		_X_ Form filed by	y One Reporting P More than One R		
(City)	(State)	(Zip)	Tab	le I - Non-l	Derivative	Securities A	Acquired, Disposed	of, or Beneficia	lly Owned	
	2. Transaction Date Month/Day/Year)	Execution any	Date, if	3. Transactio Code (Instr. 8) Code V	Disposed (Instr. 3, 4	(A) or of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Pamindar: Pano	ort on a separate line	for each cl	ass of sec	uritias hana	ficially ow	ned directly.	or indirectly			
Kennider. Kept				unites bene.	Perso inforn requir	ns who res nation cont red to resp nys a curre	spond to the colle tained in this form ond unless the fo ntly valid OMB co	n are not rm	SEC 1474 (9-02)	
	Tab					posed of, or convertible	Beneficially Owner securities)	d		

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount of
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transacti	orDerivative	Expiration Date	Underlying Securities

## Edgar Filing: BioAmber Inc. - Form 4

Security (Instr. 3)	or Exercise Price of Derivative Security		any (Month/Day/Year)	Code (Instr. 8)	Securities Acquired (A Disposed of (Instr. 3, 4, a 5)	(D)			(Instr. 3 and 4)	
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	\$ 5 <u>(1)</u>	01/26/2016		A	100,000		(2)	01/26/2026	Common Stock	100,000

## **Reporting Owners**

Reporting Owner Name / Address	Relationships					
	Director	10% Owner	Officer	Other		
Orecchioni Fabrice C/O BIOAMBER 1250 RENE-LEVESQUE BLVD WEST, SUITE 4310 MONTREAL, A8 H3B 4W8			Chief Operations Officer			
Signatures						
/s/ Jean-Francois Huc, attorney-in-fact for Fabrice Orecchioni	01	/27/2016				
<u>**</u> Signature of Reporting Person		Date				

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The exercise price represents a premium of \$0.86 per share over grant date closing market price of BioAmber Inc. common stock on the New York Stock Exchange of \$4.14 per share
- (2) These options will vest as follows: 25% will vest on 01/26/2017; the remaining 75% will vest on a monthly basis over the three (3) following years.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.